Abstract
In everyday gynecological practice, there is an unmet need to manage survivors after allogeneic hematopoietic cell transplantation (allo-HCT). The major gynecological complications include premature ovarian insufficiency (POI), chronic graft-versus-host disease (cGVHD) of the anogenital zone (cGVHDgyn), and secondary neoplasms. Aiming to assess a real-life scale of problems associated with HCT, we performed a detailed analysis of a consecutive series of females after allo-HCT who were referred for a routine gynecological evaluation. The study includes 38 females after allo-HCT in whom gynecological examination with cervical smear and USG were performed, followed by colposcopy according to NCCN guidelines. NIH scoring system was used to classify a grade of cGVHDgyn. The incidence of cGVHD was 71% whereas GVHDgyn was 29%, including 5 patients with score 3 at the time of diagnosis. The other manifestations (frequently noted) included the skin, mucosa, eyes, and liver. Menopause was diagnosed in 93% females, and in 81% of them, POI criteria were fulfilled. Ovarian function resumed in 2 cases. The rate of abnormal cytology was 26%: 4 ASCUS, 1 AGUS, 1 LSIL, 3 HSIL/ASC-H, and one cytological suspicion of cervical cancer. GVHDgyn was documented in 10 patients, and 6 of them had abnormal cervical cytology. Early topical estrogen therapy led to a significant reduction in vaginal dryness (p < 0.05), dyspareunia (p < 0.05), and less frequent cGVHDgyn (p < 0.05). GVHDgyn develops in about 30% of long-term allo-HCT survivors. Topical estrogens and hormonal replacement therapy alleviate symptoms and prevent the occurrence of severe consequences of menopause.
Highlights
The management of gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation remains still an unmet need in daily practice
The most specific and often unrecognized complication is chronic graft-versus-host disease of the anogenital zone that was reported for the first time in 1982 [3]
Four patients had score 1, two score 2, and the rest (45%) score 3, which defines the severe form of chronic graft-versus-host disease (cGVHD) according to the National Institute of Health (NIH) classification
Summary
The management of gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation (allo-HCT) remains still an unmet need in daily practice. The most specific and often unrecognized complication is chronic graft-versus-host disease (cGVHD) of the anogenital zone (cGVHDgyn) that was reported for the first time in 1982 [3]. Donor-derived immunocompetent cells can become intolerant to host tissues and recognize them as their targets, leading to the development of a unique complication called graft-versus-host disease (GVHD) [4]. The acute form (aGVHD) that occurs typically up to 100 days post-allo-HCT does not affect the genitourinary tract. Chronic GVHD which develops more than 50% of patients can involve every organ and tissue, including genital zone, with the symptomatology often mimicking autoimmune disorders. The diagnosis of cGVHD is based on the clinical
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.